Phathom Pharmaceuticals to Present at Biotech Conference
Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company dedicated to creating innovative treatments for gastrointestinal (GI) disorders, is set to feature at the Guggenheim Securities SMID Cap Biotech Conference. This event is anticipated to be a critical platform for discussions around novel treatment solutions.
Managerial Insights and Conference Details
The management team of Phathom Pharmaceuticals will take part in a fireside chat scheduled for a morning session, providing insights into the strategy and aspirations of the company in addressing GI diseases. This part of the conference will occur on a special day dedicated to interacting with attendees and discussing potential collaborations or inquiries regarding Phathom's innovations.
Participation in One-on-One Meetings
In addition to the group discussions, Phathom’s management will engage in one-on-one meetings throughout the conference. This personalized format allows for deeper conversations with stakeholders interested in the company’s pioneering work and research initiatives.
About Phathom Pharmaceuticals
Phathom Pharmaceuticals is at the forefront of biopharmaceutical innovation, concentrating its efforts on the development and distribution of unique treatments targeting gastrointestinal ailments. The company has made significant strides with its flagship product, vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB). Vonoprazan is a vital part of their product lineup, currently available in the market as VOQUEZNA tablets.
VOQUEZNA and Its Indications
VOQUEZNA is designed to treat various conditions, including heartburn associated with Non-Erosive GERD in adults. Moreover, it plays a crucial role in healing Erosive GERD and alleviating related heartburn. Phathom has also introduced VOQUEZNA TRIPLE PAK and VOQUEZNA DUAL PAK, which combine vonoprazan with antibiotics to efficiently treat H. pylori infections, showcasing Phathom's commitment to tackling complex GI challenges.
Accessing the Conference Webcast
For those interested in following the discussion and insights shared during the conference, Phathom Pharmaceuticals will provide access to a live webcast of their presentation. After the event, a recording will remain available for 90 days, allowing broader audiences to engage with the valuable information shared.
Engaging Stakeholders
Phathom Pharmaceuticals emphasizes transparent communication and invites investors and other interested parties to reach out for more details. Their strong commitment to innovation and patient care defines their approach in the biopharmaceutical landscape.
Frequently Asked Questions
1. What is the focus of Phathom Pharmaceuticals?
Phathom Pharmaceuticals is focused on developing novel treatments for gastrointestinal diseases.
2. What product is highlighted by Phathom Pharmaceuticals?
The company highlights its first-in-class potassium-competitive acid blocker, vonoprazan, sold as VOQUEZNA.
3. When does Phathom participate in the biotech conference?
Phathom will participate in the Guggenheim Securities SMID Cap Biotech Conference on February 6, 2025.
4. Where can I find more info about Phathom Pharmaceuticals?
More information about Phathom can be found on their official website and in the Events section.
5. Who can be contacted for media inquiries at Phathom?
Media inquiries can be directed to Nick Benedetto at Phathom Pharmaceuticals.
